3rd Street Diagnostics
Diagnostic targets and biomarkers make up approximately 25 percent of the Cedars-Sinai intellectual property portfolio. The majority of these assets are related to small patient populations and, for various reasons, face unique challenges with traditional technology transfer.
Thus, Cedars-Sinai's Technology Ventures developed an in-house diagnostic development business unit known as 3rd Street Diagnostics. Its purpose is to evaluate technologies in the Cedars-Sinai portfolio or to in-license particularly attractive assets. 3rd Street Diagnostics then identifies industry partners with the expertise required to facilitate a project. Ultimately, the goal is to collaborate and commercialize technologies from both Cedars-Sinai and our international partners.
Open Call for Diagnostics
Technology Ventures is interested in facilitating molecular diagnostic technologies that utilize:
- Deoxyribonucleic acid (DNA) sequencing
- Ribonucleic acid (RNA) expression
- Single and multiplex protein-based assays and cell-based tests